08 April 2026
08 April 2026
Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.
Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.
In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers, despite US import tariffs on pharmaceuticals.
Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments.
RoosterBio’s CliniControl portfolio includes cGMP MSC expansion media, exosome collection media, and bioreactor feeds.
Apnimed will initially receive $50m at the deal’s closing.
The acquisition allows Neurocrine to offer three therapies: Ingrezza, Crenessity, and Vykat XR.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
